Bristol Gate Capital Partners Inc. Sells 11,709 Shares of Zoetis Inc. (NYSE:ZTS)

Bristol Gate Capital Partners Inc. lowered its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 2.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 527,780 shares of the company’s stock after selling 11,709 shares during the quarter. Zoetis accounts for 4.2% of Bristol Gate Capital Partners Inc.’s portfolio, making the stock its 17th biggest holding. Bristol Gate Capital Partners Inc. owned about 0.12% of Zoetis worth $85,991,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. Atlantic Edge Private Wealth Management LLC increased its holdings in Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 140 shares during the period. Rakuten Securities Inc. raised its stake in shares of Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after acquiring an additional 166 shares in the last quarter. Dunhill Financial LLC boosted its position in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares in the last quarter. Murphy & Mullick Capital Management Corp acquired a new position in shares of Zoetis during the fourth quarter valued at about $44,000. Finally, Asset Planning Inc acquired a new stake in Zoetis in the 4th quarter worth approximately $58,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 4.9 %

Shares of NYSE:ZTS opened at $151.76 on Monday. The company has a market cap of $67.96 billion, a PE ratio of 27.74, a P/E/G ratio of 2.78 and a beta of 0.92. The company’s 50 day moving average is $165.71 and its two-hundred day moving average is $173.26. Zoetis Inc. has a 52 week low of $144.69 and a 52 week high of $200.33. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.32%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is presently 36.56%.

Wall Street Analysts Forecast Growth

Several research firms have commented on ZTS. StockNews.com raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Stifel Nicolaus decreased their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Barclays upped their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Morgan Stanley decreased their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Finally, Piper Sandler increased their target price on shares of Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $215.90.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the sale, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is owned by company insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.